Novel biomarkers for predicting recurrence in non-muscle invasive bladder cancer
Non-muscle invasive bladder cancer (NMIBC) is usually managed with bladder-preserving treatment, yet local recurrence is common after transurethral resection and intravesical therapy. Recurrence and progression are related but distinct: renewed disease may remain superficial, while progression to muscle-invasive disease changes prognosis. Novel biomarkers could help identify which patients need closer surveillance or additional treatment.
Current assessment uses stage, grade, tumour size and number, previous recurrence, carcinoma in situ and other clinical features. These variables remain indispensable, but they miss some biological differences. Urine, tissue, blood and immune markers may add information when they outperform routine risk factors in the intended clinical setting.
For Australian practice, the issue extends beyond analytical accuracy. A test must fit public and private follow-up, pathology workflows, regulation, reimbursement and patient access. Evidence is strongest when a marker has been tested prospectively, compared with established risk factors and linked to a management decision that improves outcomes.
Why recurrence prediction remains difficult
Most recurrence arises within the bladder and may be detected by cystoscopy, cytology or imaging, but the first recurrence is not always obvious. Tumour biology influences how often disease returns, how quickly it returns and whether it remains confined. A useful biomarker should therefore clarify the timing and intensity of surveillance rather than merely label a patient as high risk.
Risk groups are also population-dependent. A marker developed in people undergoing repeated resection at a tertiary centre may behave differently in a community setting where adherence to cystoscopy varies. Australian cohorts need consistent definitions of recurrence, adequate follow-up and representation from outside metropolitan centres.
The current and archived research at Urological Science provides a peer-reviewed setting for examining new assays and disease mechanisms. Translation depends on independent validation, reproducible assays and clear clinical thresholds, rather than small differences in sensitivity reported from selected cohorts.
Biomarker classes with the strongest clinical signal
Several biomarker families have moved beyond purely conceptual discovery. Their value differs by biological purpose, so they should not be treated as interchangeable tests.
Urine and tissue candidates
- FGFR3 and TERT mutations: common in low-grade papillary tumours and often linked to less aggressive behaviour, but they do not exclude recurrence.
- DNA methylation in ONECUT2, OTX1, TWIST1, NID2 and VIM: detects abnormal urothelial DNA shed into urine.
- Multiplex mutation and methylation panels: seek broader sensitivity while retaining a non-invasive sample.
- TP53 and CDKN2A alterations: may signal higher-risk disease, especially progression, although recurrence predictions remain inconsistent.
Blood-based and higher-resolution approaches are promising but generally less mature for routine recurrence prediction.
Exploratory approaches
- Plasma circulating tumour DNA: may reveal tumour burden between procedures, although low shedding in NMIBC limits sensitivity.
- MicroRNAs and long non-coding RNAs: reflect tumour and host states, but normalisation and assay standardisation remain difficult.
- Cytokines, angiogenic proteins and tumour-associated metabolites: potentially reflect recurrence, yet reference ranges are not standardised.
- Single-cell and immune-repertoire profiles: may explain response to intravesical immunotherapy, but cost and complexity impede routine use.
No marker covers every recurrence pattern. FGFR3 and TERT can signal lower-risk biology, whereas p53 pathway disruption and methylation abnormalities identify different risks. A limited combination with clinical variables is generally more credible than a large panel without a clear use case.
Making urine assays work in everyday practice
Urine is attractive for surveillance because collection is non-invasive and can occur alongside a routine pathology visit. The same advantages create interpretive problems: infection, haematuria, contamination, hydration and medication can affect some assays. A positive result may also reflect normal urothelial DNA rather than cancer.
Reports should separate analytical validation from clinical validation. Sensitivity and specificity describe test performance, while predictive values depend on recurrence prevalence in the studied population. A marker with strong case-control results may add little after cystoscopy, clinical risk factors and resectability are considered.
Internationally developed systems such as UroMark, Bladder EpiCheck and Cxbladder illustrate different approaches to molecular detection. Availability, TGA status, cost and local validation vary, so these products should not be treated as a single category. Repeated testing must also be linked to a prespecified pathway, or results may increase anxiety without changing care.
What tissue and blood markers add
Tissue remains valuable because it captures the clone treated at resection. FGFR3 and TERT alterations often accompany low-grade papillary disease, while TP53 mutation or CDKN2A loss is associated with a higher-risk phenotype. Spatial heterogeneity means one biopsy or resection fragment may not represent the whole tumour.
Circulating tumour DNA could overcome repeated sampling and provide a broader view of emerging clones. In NMIBC, however, tumour-derived DNA may be scarce, and a negative result is difficult to interpret. Studies must specify collection times, assay targets and how results relate to cystoscopic recurrence.
Immune markers, including programmed death-ligand 1 expression, tumour mutational burden and T-cell profiles, may distinguish patients with durable responses from those likely to relapse. Their value may be greatest after bladder-preserving immunotherapy. Australia’s tobacco-control program has reduced smoking at population level, but residual exposure and occupational contact with bladder carcinogens should still be recorded as baseline risk factors.
Turning association into clinically useful prediction
A recurrence model needs a clearly defined outcome and time origin. Recurrence at three months is clinically different from recurrence at 24 months, and a marker measured after surgery carries different information from one measured before resection. Studies should report time-to-event results and calibration across clinical risk groups.
External validation is essential, followed by prospective evaluation of utility. AUROC shows discrimination, but it does not establish whether using a marker improves a decision. Decision-curve analysis, net benefit, cost and downstream cystoscopy or treatment burden should be assessed alongside sensitivity and specificity.
Open access to methods can accelerate replication; the journal’s sample article provides a practical example of how a clinical urology paper should expose its methods and findings. Australian multicentre cohorts should include major referral centres in Melbourne and Sydney, regional hospitals and Aboriginal and Torres Strait Islander participants, with culturally safe recruitment and transparent missing-data handling.
Regulation, reimbursement and access in Australia
Commercial availability in Australia depends on what the test claims to do. A kit marketed as an in vitro diagnostic medical device generally requires inclusion in the Australian Register of Therapeutic Goods before supply, under Therapeutic Goods Administration oversight. Regulatory approval and local pathology-laboratory validation are separate milestones.
Funding creates another boundary. The Australian market combines public hospitals, private specialists, national and hospital pathology providers, and Medicare Benefits Schedule rebates. A new molecular assay is not automatically reimbursed; private health insurance or out-of-pocket payment may determine uptake. Services should compare the cost of additional testing with repeated cystoscopy, repeat resection and intravesical therapy.
Geography and data rules matter just as much. A sample collected in a regional town may need courier transport, while linked pathology, imaging and hospital records increase privacy obligations. Under the Privacy Act 1988 and Australian Privacy Principles, health information is sensitive; research use generally requires consent or another clear ethical and legal basis.
The clinical evidence can be compared directly:
| Biomarker approach | Representative markers | Evidence for recurrence | Present clinical position | Main limitation |
|---|---|---|---|---|
| Tumour mutations | FGFR3, TERT, TP53, CDKN2A | Strong prognostic biology but variable recurrence discrimination | Research adjunct to pathology | Tumour heterogeneity and sampling error |
| Urine methylation | ONECUT2, OTX1, TWIST1, NID2, VIM | Promising case-control and prospective findings | Surveillance adjunct under validation | Variable performance and limited utility studies |
| Multiplex urine panels | UroMark, Bladder EpiCheck, Cxbladder | Mixed results across populations | Potential role after local validation | Availability, cost and generalisability |
| Plasma circulating tumour DNA | Tumour-specific DNA variants | Encouraging early evidence | Primarily research use | Low shedding and limited sensitivity |
| Immune and soluble markers | PD-L1, microRNAs and cytokines | Heterogeneous and evolving evidence | Research setting | No standardised recurrence thresholds |
Multiplex urine tests have the strongest fit for surveillance research, while tissue and blood markers remain valuable research tools and potential decision aids. None yet replaces cystoscopy or established clinical risk factors.
Building recurrence-aware follow-up pathways
Adoption should begin with a defined use case. One pathway might use a validated urine panel to identify patients needing an earlier cystoscopy or closer urine surveillance; another might use tissue markers to intensify intravesical treatment. The selected marker must improve a decision that can be made with current pathology and imaging.
Urologists, pathologists and nurses should agree on specimen collection, reporting, repeat-testing intervals and actions for discordant results. Patients should receive plain explanations of uncertainty, false positives and false negatives. Clear scientific and patient communication can be supported through medical writing resources.
The immediate call to action is to establish Australian validation cohorts, publish transparent performance data and evaluate clinical utility before routine testing. Health services should specify which biomarkers are available, what patients will pay and how results will change surveillance. This focused pathway can reduce unnecessary procedures while ensuring that high-risk recurrence is recognised earlier across urban and regional Australia.